Helix BioPharma Corp

Helix BioPharma operates with a current liquidity position of CAD 15.59 million in total equity and CAD 3.22 million in total liabilities, yielding a debt-to-equity ratio of 0.02 and a current ratio of 0.13, indicating limited short-term liquidity. The company reported negative operating and free cash flows of CAD 3.83 million and CAD 5.20 million, respectively, in the latest period. Profitability metrics show a return on equity (ROE) of -33.4% and a return on assets (ROA) of -27.7%, both significantly below the industry median for biotechnology firms, which typically report positive ROE and ROA in the 10-20% range. These figures reflect the company's pre-revenue status and high R&D expenditures. The company's revenue is entirely derived from its pipeline of immuno-oncology therapies, with no disclosed geographic diversification in the input data. All revenue is expected to come from the commercialization of its lead candidate, L-DOS47, and pre-IND candidates LEUMUNA and GEMCEDA. Outlook data indicates a continuation of negative operating performance, with no revenue growth expected in the current fiscal year. The company is projected to maintain a negative net income trajectory, with no material change in operating cash flow or free cash flow in the next fiscal year. Risk factors include medium liquidity risk due to negative net cash after subtracting total debt, and low dilution risk based on the current share structure. The company has not disclosed any recent equity issuance or dilutive events in the input data. Recent filings and transcripts highlight the advancement of L-DOS47 into Phase Ib trials and the initiation of pre-IND studies for LEUMUNA and GEMCEDA. No material regulatory or litigation events were disclosed in the input data.